

Short Bowel Syndrome - Pipeline Review, H2 2019

<https://marketpublishers.com/r/S58364DF38FEN.html>

Date: December 2019

Pages: 67

Price: US\$ 2,000.00 (Single User License)

ID: S58364DF38FEN

Abstracts

Short Bowel Syndrome - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome - Pipeline Review, H2 2019, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape.

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Short Bowel Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Short Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Short Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by

Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 3, 1, 7 and 1 respectively.

Short Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Short Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Short Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Short Bowel Syndrome (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Short Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Short Bowel Syndrome - Overview

Short Bowel Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Short Bowel Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Short Bowel Syndrome - Companies Involved in Therapeutics Development

Adocia SAS

enGene Inc

Hanmi Pharmaceuticals Co Ltd

Huons Global Co Ltd

Micelle BioPharma Inc

Naia Rare Diseases Inc

OPKO Health Inc

Pfizer Inc

PhaseBio Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Worphmed Srl

Zealand Pharma AS

Short Bowel Syndrome - Drug Profiles

apraglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exenatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Short Bowel Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glepaglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HL-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-15912 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOD-1501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-403 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-681 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teduglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teduglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZP-7570 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Short Bowel Syndrome - Dormant Projects

Short Bowel Syndrome - Discontinued Products

Short Bowel Syndrome - Product Development Milestones

Featured News & Press Releases

Jun 26, 2019: Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome

May 17, 2019: Therachon to present data from ongoing Phase II Study of Apraglutide for Short Bowel Syndrome at Digestive Disease Week

May 17, 2019: U.S. FDA approves GATTEX (teduglutide) for children 1 year of age and older with Short Bowel Syndrome

May 07, 2019: Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome

May 03, 2019: Hanmi's short bowel syndrome treatment becomes orphan drug in US

Mar 25, 2019: Therachon presents data from preclinical and phase I clinical studies of Apraglutide for the treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference

Feb 05, 2019: Pharm-Olam enrolls patients in Zealand Pharma orphan drug study

Jan 16, 2019: Therachon is granted Orphan Drug Designation by US FDA for Apraglutide for the treatment of Short Bowel Syndrome

Nov 29, 2018: Therachon is granted Orphan Drug Designation in the European Union for apraglutide for the treatment of short bowel syndrome

Nov 13, 2018: U.S. FDA accepts for filing Shire's supplemental New Drug Application for GATTEX (teduglutide [rDNA origin]) for children with Short Bowel Syndrome

Oct 05, 2018: Zealand Pharma enrolls first patient in Phase III study of glepaglutide

May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.

Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome

Apr 09, 2018: Revestive is accepted for restricted use within NHS Scotland

Jan 23, 2018: New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Short Bowel Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Short Bowel Syndrome - Pipeline by Adocia SAS, H2 2019
Short Bowel Syndrome - Pipeline by enGene Inc, H2 2019
Short Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2019
Short Bowel Syndrome - Pipeline by Huons Global Co Ltd, H2 2019
Short Bowel Syndrome - Pipeline by Micelle BioPharma Inc, H2 2019
Short Bowel Syndrome - Pipeline by Naia Rare Diseases Inc, H2 2019
Short Bowel Syndrome - Pipeline by OPKO Health Inc, H2 2019
Short Bowel Syndrome - Pipeline by Pfizer Inc, H2 2019
Short Bowel Syndrome - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2019
Short Bowel Syndrome - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Short Bowel Syndrome - Pipeline by Worphmed Srl, H2 2019
Short Bowel Syndrome - Pipeline by Zealand Pharma AS, H2 2019
Short Bowel Syndrome - Dormant Projects, H2 2019
Short Bowel Syndrome - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Short Bowel Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Adocia SAS

enGene Inc

Hanmi Pharmaceuticals Co Ltd

Huons Global Co Ltd

Micelle BioPharma Inc

Naia Rare Diseases Inc

OPKO Health Inc

Pfizer Inc

PhaseBio Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Worphmed Srl

Zealand Pharma AS

I would like to order

Product name: Short Bowel Syndrome - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/S58364DF38FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S58364DF38FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970